Supply Chain Wizard for Pharma

Hosted by Evren Ozkaya, Ph.D.

BusinessInterviews guests

Website RSS feed

Episodes

Latest episode

Oct 2026

Language

About the show

Empowering Pharma Industry Leaders for Digital Excellence! Supply Chain Wizard for Pharma guides manufacturing and supply chain professionals to become a Wizard of Change in the era of digital transformation. Join our host Evren Ozkaya, Ph.D, as he welcomes thought leaders and industry experts from operations, commercial and technology domains around the world on the latest trends, case studies, best practices and insights in the pharmaceutical and life science industries.

Listen to episodes

29 recent

October 22, 2026Episode 2937 min

Dose #29: Procurement as a Strategic Driver of Profit in Pharma with Elena Polansky (Phibro Animal Health)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Elena Polansky, Chief Procurement Office/ Vice President Global Sourcing & Procurement at Phibro Animal Health, to explore the strategic role of procurement in the pharmaceutical industry and how digitalization and AI are reshaping the function. The conversation begins with Elena's career journey from consulting to more than 20 years in the pharmaceutical industry, including leadership roles at Pfizer and BioMarin and lastly Phibro Animal Health. Having served as Head of Procurement at Pfizer and Chief Procurement Officer at BioMarin, Elena shares how she now brings her experience to small and medium-sized pharma companies through Somerset Phibro Animal Health, with a core thesis that a strong procurement organization can drive profit. Evren and Elena then discuss how procurement fits into the end-to-end pharmaceutical supply chain. Elena argues that procurement should not be viewed simply as a cost center. In an industry where delivering high-quality medicines to patients is mission critical, procurement influences much more than price. Decisions around suppliers, CDMOs, and in-house production can directly impact a company's strategy, capacity, quality, and risk management. The discussion then shifts to digital transformation and AI. Elena highlights the opportunity to use technology to reduce friction throughout the procure-to-pay cycle, from purchasing and catalogues to legal and payment processes. She also points to the challenges created by fragmented ERP systems, particularly in larger organizations where technology does not always provide a single source of truth or easily actionable information across the end-to-end supply chain. Evren and Elena explore how AI can transform the relationship between buyers and suppliers by enabling faster analysis of data, improving visibility into spending, and automating repetitive procurement activities. However, Elena emphasizes that human-in-the-loop processes will remain essential, with AI supporting decision-making rather than replacing the judgment and expertise of procurement professionals. They also discuss the importance of supplier relationships, particularly in a capacity-constrained CDMO and CMO market. Elena explains why pharma companies need to carefully balance their supplier base: maintaining relationships with smaller suppliers can provide valuable innovation, while excessive supplier fragmentation can create unnecessary complexity. Selecting contractors with the right culture, technology infrastructure, and long-term vision is equally important for building sustainable partnerships. The conversation also examines pricing transparency and the importance of sustainable supplier economics. Elena highlights how factors such as energy prices, tariffs, and changing market conditions can affect supplier costs, while emphasizing that both pharma companies and contractors need to approach pricing transparently rather than using cost changes opportunistically to expand margins. Finally, Evren and Elena discuss the opportunities procurement can create for small and medium-sized pharma companies. With margin expansion becoming an increasingly important priority for CFOs and finance leaders, Elena identifies procurement as an area where companies can find relatively quick wins by evaluating whether their suppliers truly support their business strategy. Evren and Elena conclude by discussing career advice for the next generation of procurement professionals. Elena emphasizes the importance of maintaining relationships, continuously learning, understanding the broader business beyond cost, and getting closer to the manufacturing floor. For procurement professionals, understanding quality, innovation, reliability, and business strategy alongside cost is essential to becoming a true strategic partner.

September 4, 2026Episode 2836 min

Dose #28: Is Pharma Ready for AI? The Digital Maturity Challenge with Evren Ozkaya (SCW.AI)

In this special episode of SCW for Pharma, the usual roles are reversed: Evren Ozkaya, Ph.D., Founder and CEO of SCW.AI, steps in as the guest alongside host Joe Agresta, Assistant Professor and Program Director of the Master of Science Supply Chain Analytics Program at Rutgers Business School. The conversation explores Evren’s journey across supply chain, consulting, and entrepreneurship, addressing a crucial question: Is pharmaceutical manufacturing truly ready for AI? Evren shares his trajectory from studying industrial engineering and continuing his education at Georgia Tech to working at Intel, McKinsey, and Sandoz/Novartis. While navigating pharma track-and-trace regulations in 2013, he recognized the industry's low digital maturity. Driven by a desire to avoid solving the same problem repeatedly, he founded Supply Chain Wizard as a consulting firm. Addressing packaging line efficiency led to the creation of the OEE Tracker, eventually evolving the company into SCW.AI—an Pharma 4.0 provider offering a Digital Factory Platform that integrates monitoring, execution, compliance, planning, IoT, and AI. Today, SCW.AI has completed over 500 projects with more than 40 pharma companies. Turning to digital transformation, Evren identifies change management as pharma manufacturing's main rate-limiting factor. Paper- and Excel-driven workflows, limited machine connectivity, fragmented data, and legacy mindsets continue to hinder progress. He stresses that technology alone is insufficient; lasting transformation requires leadership alignment, change champions, and bottom-up engagement that wins the trust of shop floor operators. Addressing the "elephant in the room"—artificial intelligence—Evren explains why AI should not be the starting point, despite it being in SCW.AI’s name. He introduces a three-dimensional framework centered on Data, Dashboards, and Decisions. Reliable AI-driven decisions require granular, real-time, automated data collection and contextualized information first. Currently, only a small minority of pharma facilities possess the digital maturity needed to deploy AI at scale, as data remains trapped in paper, spreadsheets, and disconnected silos. A Digital Factory establishes this critical foundation by unifying assets, production, workforce, SOPs, batch records, and scheduling into a harmonized ecosystem where humans and AI can evaluate factory operations holistically. Looking ahead, Evren predicts pharma’s modernization will accelerate rapidly rather than taking decades, driven by growing executive enthusiasm. He closes with advice for future supply chain leaders: build broad supply chain fundamentals, cultivate deep domain expertise, develop digital literacy, and remain relentlessly curious. Building a more efficient pharmaceutical industry requires advanced technology paired with people committed to continuous learning and driving meaningful change.

August 24, 202640 min

Dose #27: Beyond Capacity: How CDMOs Can Win the Future with Robert Hayes (Hayes Healthcare)

In this episode of SCW for Pharma, host Evren Ozkaya welcomes Robert Hayes, Founder and Principal of Hayes Healthcare. Drawing on more than 30 years of experience across pharmaceutical manufacturing, MedTech, supply chain, commercial leadership, and executive management, Robert shares the lessons that took him from the shop floor to leading a publicly traded company. The conversation begins with Robert reflecting on his manufacturing roots at companies including Fresenius Kabi, Boston Scientific, Cardinal Health, and Amcor. He explains how hands-on experience in high-volume manufacturing and pharmaceutical quality helped him build the technical expertise and problem-solving skills that later enabled his transition into business development and executive leadership. Evren and Robert then discuss how the COVID-19 pandemic reshaped pharmaceutical manufacturing and supply chains. They explore how exposed vulnerabilities accelerated reshoring efforts, increased investments in domestic manufacturing capacity, and prompted companies to rethink long-term supply chain resilience. Looking ahead, Robert identifies home-based therapies and drug delivery devices, such as auto-injectors, as one of the next major opportunities and challenges for the industry. As treatments increasingly move closer to patients, manufacturers and CDMOs must develop solutions that combine reliability, scalability, and ease of use. The discussion then turns to the future of CDMOs. Robert argues that capacity and quality are no longer enough to stand out. Instead, CDMOs must become strategic partners by understanding their customers' products, strengthening risk management, and helping pharmaceutical companies solve broader operational challenges. They also discuss how digital transformation, connected data, and AI can improve agility, quality, and decision-making, enabling CDMOs to deliver greater value in an increasingly competitive market. Evren and Robert conclude the conversation by emphasizing the importance of building strong technical foundations, staying close to customers, and embracing continuous learning. Robert encourages the next generation of leaders to pursue work they are passionate about while remaining adaptable in a rapidly evolving pharmaceutical industry.

June 11, 2026Episode 2652 min

Dose #26: Quality, Compliance, and the Future of Indian Pharma with Rajeev Kumar (Biological E. Limited)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Rajeev Kumar, Vice President at Biological E. Limited, a leading vaccine manufacturer and CDMO. Drawing on nearly three decades of experience across pharmaceutical manufacturing, supply chain management, and digital excellence, Rajeev shares his perspective on the evolution of the Indian pharmaceutical industry and the growing importance of quality, compliance, and digitalization. The conversation begins with Rajeev reflecting on how pharmaceutical manufacturing has changed since he entered the industry in the late 1990s. He explains that early pharmaceutical production focused heavily on antibiotics and APIs, where processes were comparatively straightforward and compliance requirements were less demanding. As the industry shifted toward vaccines, biologics, and other complex therapies, manufacturers faced significantly greater expectations around batch validation, data integrity, and audit readiness. Evren and Rajeev then explore the competitive advantages that have helped India become a global pharmaceutical powerhouse. While lower labor costs and large-scale manufacturing capabilities have historically contributed to India's success, Rajeev argues that the industry's strength today extends beyond cost leadership. He highlights India's growing expertise in producing complex biologics and vaccines at scale, supported by a highly skilled workforce and strong engineering capabilities. The discussion then turns to digital transformation and its role in improving productivity and reducing manufacturing costs. Rajeev explains that for advanced products such as mRNA vaccines and biologics, reproducible processes are essential. Monitoring yield, quality, and operational performance in real time requires digital technologies that support consistent execution and data-driven decision-making. He notes that while India continues to maintain cost advantages, future competitiveness will increasingly depend on talent, innovation, and manufacturing excellence. In the second half of the conversation, Rajeev provides a practical introduction to ALCOA+, one of the foundational frameworks for pharmaceutical data integrity. He explains the principles of Attributable, Legible, Contemporaneous, Original, and Accurate data, along with the additional requirements that data must be Complete, Consistent, Enduring, and Available. Rajeev demonstrates how technologies such as electronic batch records, digital logbooks, e-signatures, automated data collection, IoT connectivity, and cloud-based systems help manufacturers satisfy these requirements while improving operational efficiency. The discussion highlights an important connection between compliance and productivity. Rajeev explains that high-quality, automated data not only supports regulatory requirements but also enables better decision-making across manufacturing operations. As a result, investments in digital technologies often create benefits that extend far beyond compliance alone. Finally, Evren and Rajeev examine the future of digitalization in pharmaceutical manufacturing. While many companies still rely heavily on paper-based processes, Rajeev believes manufacturers must adopt digital transformation strategies that align with their level of digital maturity. Looking ahead, he suggests that as regulatory expectations continue to evolve, technologies such as digital logbooks and electronic batch records may become increasingly necessary—and potentially mandatory—for maintaining compliance and meeting future GMP requirements. Evren and Rajeev conclude their insightful conversation by emphasizing that quality, compliance, and digital transformation are becoming inseparable. As pharmaceutical manufacturing continues to advance toward more complex therapies, organizations that combine strong data integrity practices with modern digital technologies will be best positioned to achieve both regulatory excellence and operational performance.

May 4, 2026Episode 2542 min

Dose #25: The Evolving Role of Supply Chains and Future Skills with Abe Eshkenazi (ASCM)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Abe Eshkenazi, Chief Executive Officer of the Association for Supply Chain Management (ASCM). The conversation begins with Abe’s professional journey, starting from his early career in pharmaceutical operations, including manufacturing and supply chain management. He shares how his current role focuses on helping organizations build more agile, resilient, and risk-aware supply chains, while also fostering a global community that advances the profession across areas such as strategy, geopolitics, compliance, and sustainability. Evren and Abe then explore how the perception of the supply chain has evolved since COVID-19. Abe emphasizes that supply chain is no longer a back-office function but a critical topic at the C-level. The pandemic exposed major gaps in transparency and visibility, pushing organizations to rethink their priorities beyond cost and efficiency to include resilience, ethics, and sustainability. The discussion then shifts to the gap between academic education and real-world supply chain challenges. Abe reflects on how supply chain management was not historically a dedicated academic discipline and how many professionals entered the field from engineering or finance backgrounds. He highlights the role of certification and continuous education programs in bridging this gap, as well as ASCM’s contributions in this regard. Evren and Abe also discuss the importance of continuous learning and cross-functional development. Abe underscores that supply chain professionals must go beyond operational efficiency, developing capabilities in finance, analytics, sustainability, and strategy. At the same time, he highlights the growing importance of soft skills, including relationship management and the ability to navigate complex, dynamic environments while balancing short-term disruptions with long-term strategic goals. The conversation then touches on ASCM’s documentary “The Chain: How The World Works,” which illustrates the hidden complexity of global supply chains and is streaming on Amazon Prime. Abe explains how supply chains impact everyday life in ways most people do not realize until disruptions occur, emphasizing that supply chains are ultimately human systems that directly affect societies and livelihoods. Focusing on the pharmaceutical and life sciences sector, Abe highlights the critical importance of quality, accessibility, and reliability. He explains that pharma supply chains go beyond operational complexity, as they are directly linked to patient health and wellbeing. He also points to global dependencies, such as the concentration of active pharmaceutical ingredient (API) production, and exposed vulnerabilities in ensuring access to essential medicines. Looking ahead, Abe identifies the skills that will be most in demand over the next five years. He emphasizes the growing importance of leadership, communication, and collaboration skills, as supply chain professionals must translate complex insights into actionable strategies across organizations. With increasing geopolitical uncertainty, technological advancement, and demand volatility, the ability to influence and align stakeholders will be critical. Finally, Abe shares his perspective on talent in the healthcare sector. He highlights the need to recruit individuals who are motivated by impact and committed to improving people’s lives. While digital transformation is essential for improving visibility and efficiency, he stresses that technology should be seen as a tool, not a replacement for human judgment. Evren and Abe conclude the conversation with a powerful reflection: supply chain is not a support function, but a critical, cross-functional discipline that plays a vital role in delivering what people need, when they need it—ultimately making a meaningful difference in the world.

March 9, 2026Episode 2451 min

Dose #24: Capacity Utilization and the Future of CDMOs with Tim Tyson (TriRx Pharmaceutical Services)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Tim Tyson, Chairman and CEO of TriRx Pharmaceutical Services. The conversation begins with Tim’s professional journey in the pharmaceutical industry. Starting his career in operations and manufacturing, he worked closely with major pharmaceutical companies before rising to executive leadership roles at GSK, where he served as the president of the Global Manufacturing and Supply Division. Tim reflects on what continues to resonate with him about the pharmaceutical industry: the opportunity to contribute to life-altering and life-saving medicines that have a meaningful impact on patients around the world. Evren and Tim then compare the pharma services (CDMO) industry with consumer goods manufacturing. While the industries differ in many ways, Tim highlights a surprising similarity: both operate with relatively tight margins, making operational efficiency and continuous improvement essential for long-term competitiveness. The discussion then shifts to Tim’s perspective on the Contract Development and Manufacturing Organization (CDMO) business model. Tim explains that outsourcing specialized manufacturing capabilities allows pharmaceutical companies to increase efficiency and reduce costs, particularly when CDMOs can achieve higher capacity utilization across their facilities. He emphasizes that making the right investments in facilities and technologies is essential for serving both human and animal health markets effectively. A major challenge across the industry, however, is low capacity utilization. Tim notes that average utilization rates can be as low as 24%, while a sustainable business typically requires at least 40–45%. Although many CDMOs target utilization rates closer to 70%, regulatory constraints and market dynamics often make this difficult to achieve. According to Tim, improving utilization and operational efficiency will be critical for the long-term sustainability of pharmaceutical manufacturing. Evren and Tim also discuss the recent wave of investments in new pharmaceutical factories, particularly in the United States. Tim argues that from both an engineering and financial perspective, building new facilities may not always be the most rational solution when significant unused capacity already exists. Instead, he advocates for modernizing existing facilities, adopting new technologies, and improving operational performance to unlock value from current infrastructure. At the same time, the industry is experiencing growing regionalization, with reshoring trends emerging not only in the U.S. but also across Europe, China, and India. The conversation then turns to the role of visibility and digitalization in pharmaceutical manufacturing. Tim emphasizes that successful CDMOs must build strong customer relationships based on trust and consistently deliver products that meet regulatory standards and arrive on time and in full. Achieving this requires moving beyond fragmented spreadsheets toward digital factories that provide real-time operational visibility. With better data and transparency, organizations can identify hidden inefficiencies, drive continuous improvement, and maximize operational performance. Finally, the discussion addresses the growing interest in AI across the pharmaceutical sector. Tim believes predictive tools can provide meaningful value in manufacturing environments, particularly for identifying improvement opportunities and supporting data-driven decision-making. However, he stresses that organizations must first establish strong data foundations before.

January 27, 2026Episode 2352 min

Dose #23: Scaling Biologics CDMOs, Capacity, and Digitalization with Kevin Sharp (Samsung Biologics)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Kevin Sharp, Executive Vice President and Head of Sales and Operations at Samsung Biologics. Kevin shares his more than 20 years of experience in the pharmaceutical industry, spanning procurement, manufacturing, supply chain, and business development roles across companies such as GSK, Contract Pharmacal Corp, and Samsung Biologics. With the last decade focused on biologics, he offers a broad and practical perspective on how the industry has evolved. The conversation begins with an overview of Samsung Biologics and its position in the CDMO market. Founded in 2011, Samsung Biologics has rapidly become a leader in biologics manufacturing capacity, leveraging Samsung’s deep engineering expertise and manufacturing DNA. Kevin explains how the company’s end-to-end CDMO model addresses one of the biggest pain points for biopharma companies: the cost, risk, and time associated with tech transfers across multiple suppliers. Evren and Kevin then dive into the unique complexity of biologics supply chains. Kevin highlights how longer planning horizons, strict quality requirements, and capacity slot management make timing and end-to-end coordination critical. As molecules become more complex and new drug modalities emerge, even small disruptions in sequencing or release timing can have significant consequences for quality and supply reliability. The discussion expands to broader biopharma trends, including the growing share of combination therapies and novel modalities. Kevin notes that a significant portion of products expected to be approved in the coming years will fall outside traditional standards, putting pressure on CDMOs to invest in modern facilities, scalable platforms, and standardized yet flexible production processes. He emphasizes that while there is room in the market for CDMOs of all sizes, larger players differentiate themselves through integrated, one-stop-shop capabilities and scalable capacity. Digitalization is another key theme of the episode. Kevin explains how Samsung Biologics applies its technology-driven heritage to biologics manufacturing, drawing parallels between semiconductor production and biopharma in terms of precision and environmental control. He discusses the use of MES, supply chain visibility tools, AI, and digital twins, and how real-time data transparency creates value for clients while improving consistency and operational performance. Finally, Evren and Kevin explore why digital transformation remains slow across much of the pharma CDMO landscape. Kevin points to investment requirements, long implementation timelines, sunk costs, and concerns about technology obsolescence as major barriers. He also shares advice for younger professionals in the industry, encouraging early exposure to different functions and the importance of building strong, long-term relationships. They conclude by reflecting on how capacity, technology, and adaptability will continue to shape the future of biologics manufacturing, and why companies that commit early to scalable platforms and digital foundations are likely to widen the gap in the years ahead.

January 8, 2026Episode 2245 min

Dose #22: Reducing Downtime and Unlocking Hidden Capacity in Pharma Manufacturing with Andrea Wagner (PharmaPhixx)

In this episode of SCW for Pharma, Evren Ozkaya welcomes Andrea Wagner, CEO of PharmaPhixx. The conversation begins with Andrea’s professional background, spanning academia and industry. She holds a doctorate in toxicology and a master’s degree in analytical chemistry and spent the early part of her career in universities before transitioning into the pharmaceutical industry. Andrea later co-founded a CDMO, built a manufacturing operation from the ground up, and successfully exited the business (Berkshire Sterile Manufacturing). In 2023, she founded PharmaPhixx, a company focused on helping CMOs and CDMOs reduce the negative impact of production downtime by partnering with pharma manufacturers, OEMs, and engineering organizations. Andrea also highlights her commitment to mentoring women in engineering and pharma, noting that the “xx” in PharmaPhixx represents women. Building a CDMO & Market Dynamics Evren and Andrea discuss the high barriers to entry in the CDMO sector, noting it took 18 months post-construction to secure a first client—a testament to the industry's long operational timelines. Regarding domestic capacity shifts in the U.S., Andrea argues that "overcapacity" is relative; while some segments are saturated, others remain constrained. She emphasizes that true capacity isn’t just about floor space—it requires years of regulatory approval and trust-building. The conversation highlights a major industry pain point: average equipment utilization (OEE) is only around 35%. Andrea explains how PharmaPhixx uses automation, robotics, and AI to minimize downtime and handle repetitive tasks, freeing engineers for higher-value work. Despite the industry’s slow digital adoption, she predicts a total transformation of pharma factories within the next decade, driven by the need for better data to improve P&L performance. Andrea identifies "operational firefighting" and financial constraints as the primary hurdles to modernization. She suggests that instead of relying on external advisors, senior management should empower internal operations teams—who understand the bottlenecks best—with the time and resources to innovate. The shift from paper-based systems to digital batch records is cited as the essential first step for AI applications like automated quality inspection. Andrea expects the FDA and EMA to accelerate the push for paperless systems as a younger, tech-savvy workforce takes over. The episode concludes with advice for young professionals and women in pharma. Andrea encourages them to build strong support networks and seek mentorship, reaffirming her commitment to developing the next generation of industry leaders.

December 5, 2025Episode 2144 min

Dose #21: Supply Chain Planning for Advanced Therapies and Overcoming Complexity with Tom Walls (Spark Therapeutics)

In this episode of SCW for Pharma, host Evren Ozkaya welcomes Tom Walls, former Head of Supply Chain Planning at Spark Therapeutics, a Roche company. The conversation kicks off with Tom sharing his career evolution from small molecules to his current focus on advanced therapy medicinal products, expressing his optimism for the potential of cell and gene therapies to treat many previously untreatable rare diseases. Evren and Tom then explore the different types of advanced therapies, clarifying that some are highly personalized (batch for a single patient) while others follow a bulk production model, all targeting rare diseases but never reaching the scale of high-volume small molecule drugs. The discussion then delves into the unique complexities of the cell and gene therapy supply chain. Tom outlines several challenges, including highly variable yields, the need for skilled teams for stability studies, small batch sizes leading to production difficulties, and the hurdles of country-specific regulations. He underscores that the short 36- to 72-hour shelf life necessitates precise scheduling, and the high cost of manufacturing capacity makes idle time a financial challenge. Tom confirms that this inherent complexity is a primary factor contributing to the therapies' high price points, often reaching the million-dollar plus range. Evren and Tom shift their focus to what defines a strong planning organization in this specialized field. Tom explains that top performers are clear communicators who make confident, data-aware decisions and can quickly align teams during unexpected issues. He highlights that planning covers several areas, including analytical, regulatory, and clinical planning, with risk management being central. Tom notes that while AI-driven production scheduling can help manage complexity and yield variability that traditional ERPs miss, the technology landscape remains fragmented, lacking a single holistic platform that covers regulatory, supply chain, demand planning, production scheduling and production monitoring domains. The conversation continues by examining the need to link planning and execution systems on top of others to understand the impact of decisions, especially with yield variability. Bringing planning and execution closer together supports optimization and strengthens communication, since plan adjustments need to translate into clear actions for teams on the ground. Evren then asks about tariffs, trade tensions, and reshoring in the United States. Tom explains that many inputs, from plasma materials to tubing components, come from China. While the US is large, not everything can be reshored due to the specialized nature of these materials. Decisions must be made carefully. They close by examining the role of AI in cell and gene therapy. Tom highlights the importance of linking regulatory, supply chain, demand planning, and execution. He sees opportunities in digital twins and anomaly detection to help teams manage risk more effectively. In the final segment, Tom shares the advice he would give his younger self. He wishes he had worked at more production sites to better understand how different operations run and how planning decisions affect people in manufacturing. He also would have spent more time with finance and regulatory teams, since planning sits at the intersection of all these functions. He encourages future professionals to build skills across these domains to succeed in this field.

October 20, 2025Episode 2031 min

Dose #20: Agility, AI, & the Modern Generic Supply Chain with Katja Lumbar Globocnik (Insud Pharma)

In this episode of SCW for Pharma host Evren Ozkaya welcomes Katja Lumbar Globocnik, Head of U.S. Supply Chain at Exeltis and Xiromed, subsidiaries of Insud Pharma. Katja brings decades of experience across global pharmaceutical supply chains, from her early days in Europe with companies like Novartis and Sandoz to leading countless generic product launches at Teva in the United States. Evren and Katja open their discussion by comparing the dynamics of large versus small-to-mid-sized pharma companies. Katja explains how larger organizations, while rich in structure and learning opportunities, can be slowed by bureaucracy. In contrast, smaller companies operate with greater agility, allowing individuals to take broader ownership of decisions and execution. This leaner environment, she notes, cultivates problem solvers. The conversation then turns to digitalization and system maturity. Contrary to expectations, Katja argues that size doesn’t guarantee sophistication. Many large companies still rely on traditional operations, while smaller firms like Insud Pharma have adopted advanced technologies, including AI-driven analytics and automation. These tools, she explains, are transforming supply chains by accelerating decision-making, enabling real-time visibility, and automating repetitive tasks. Evren and Katja also examine the management of operational excellence in multi-site environments. Katja sees clear value in driving OpEx globally, while acknowledging the growing trend toward regionalization. Together, they emphasize the importance of balancing standardization with local flexibility—especially as cloud-based systems make real-time benchmarking and performance tracking across sites possible. When discussing product launches, Katja highlights the excitement and challenges of bringing generic medicines to market. Success, she says, depends on teamwork, scenario planning, and calm risk assessment—particularly in the U.S., where speed to market is critical. Finally, the discussion circles back to digital transformation at manufacturing sites. Katja identifies alignment, investment constraints, and resistance to transparency as common barriers. Still, she believes progress is inevitable, led by plant leaders who take a holistic view, embrace visibility, and see weaknesses as opportunities for improvement. Evren closes by asking Katja what advice she would give her younger self. Her answer is simple and powerful: “Be fearless. Learn as much as you can. Go for it until someone stops you.”